Patents by Inventor Katrin Groebke Zbinden

Katrin Groebke Zbinden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210277020
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using the compounds and methods of determining the monoacylglycerol lipase (MAGL) inhibitory activity of the compounds.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 9, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lilli ANSELM, Joerg BENZ, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Dominik HEER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Fionn O`HARA, Hans RICHTER
  • Patent number: 11091471
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: August 17, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Giuseppe Cecere, Bernhard Fasching, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Emmanuel Pinard, Andrew Thomas
  • Publication number: 20210107920
    Abstract: The invention provides new heterocyclic compounds having the general formula (Ic) wherein A, L, X, m, n and R20 to R23 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 18, 2020
    Publication date: April 15, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Dennis Jul HANSEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Fionn O'HARA, Hans RICHTER, Martin RITTER, Satoshi TSUCHIYA, Rui CHEN
  • Publication number: 20210094943
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and RI to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 10, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
  • Publication number: 20210094945
    Abstract: The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Andres Miguel Olivares Morales, Angélique Patiny-Adam, Emmanuel Pinard, Valerie Runtz-Schmitt, Sandra Steiner
  • Publication number: 20210094973
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L1, X, m, n and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 22, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER
  • Publication number: 20210061760
    Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 4, 2021
    Inventors: Katrin Groebke Zbinden, Roger Norcross, Phillippe Pfileger
  • Publication number: 20200308190
    Abstract: The invention provides new heterocyclic compounds having the general formula wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: April 9, 2020
    Publication date: October 1, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER, Didier ROMBACH, Martin KURATLI
  • Publication number: 20200048194
    Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    Type: Application
    Filed: October 15, 2019
    Publication date: February 13, 2020
    Inventors: Katrin Groebke Zbinden, Roger Norcross, Phillippe Pfileger
  • Patent number: 10501411
    Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: December 10, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Katrin Groebke Zbinden, Roger Norcross, Philippe Pflieger
  • Publication number: 20190300516
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 5, 2019
    Publication date: October 3, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bernd BUETTELMANN, Giuseppe CECERE, Bernhard FASCHING, Katrin GROEBKE ZBINDEN, Maria-Clemencia HERNANDEZ, Henner KNUST, Andreas KOBLET, Emmanuel PINARD, Andrew THOMAS
  • Patent number: 10399985
    Abstract: The present invention relates to compounds of formula I, wherein A, B, R1, R2, and Z are as defined hereinbefore.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 3, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden
  • Patent number: 9932335
    Abstract: The present invention relates to compounds of formula wherein R1, Y1, Y2, X, R and n are as defined herein.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 3, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Theresa Maria Ballard, Emmanuel Pinard, Herve Schaffhauser, Katrin Groebke Zbinden, Thomas Ryckmans, Alexander Flohr
  • Patent number: 9708302
    Abstract: The present invention relates to compounds of formula wherein R1 is C4-6-cycloalkyl or C4-6-heterocycloalkyl, which are optionally substituted by one or two substituents, selected from hydroxy or lower alkyl; A is phenyl, pyridinyl or piperidinyl; R2 is hydrogen, halogen, lower alkyl, cyano, C4-6-cycloalkyl, lower alkoxy, lower alkoxy substituted by halogen, or is a five- or six-membered heteroaryl, optionally substituted by lower alkyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: July 18, 2017
    Assignee: HOFFMANN-LA-ROCHE INC.
    Inventors: Katrin Groebke Zbinden, Emmanuel Pinard, Thomas Ryckmans
  • Patent number: 9708259
    Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable addition salts, racemic mixtures or the corresponding enantiomers and optical isomers thereof. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain and sleep disorder.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 18, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Theresa M. Ballard, Katrin Groebke Zbinden, Emmanuel Pinard, Thomas Ryckmans, Herve Schaffhauser, Jean-Baptiste Blanc
  • Patent number: 9617271
    Abstract: The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: April 11, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Christian Lerner
  • Patent number: 9540384
    Abstract: The invention relates to compounds of formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: January 10, 2017
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden, Matthias Koerner, Christian Lerner
  • Publication number: 20160333018
    Abstract: The present invention relates to compounds of formula I, wherein A, B, R1, R2, and Z are as defined hereinbefore.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 17, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alexander Flohr, Katrin Groebke Zbinden
  • Publication number: 20160326144
    Abstract: The present invention relates to compounds of formula wherein R1 is C4-6-cycloalkyl or C4-6-heterocycloalkyl, which are optionally substituted by one or two substituents, selected from hydroxy or lower alkyl; A is phenyl, pyridinyl or piperidinyl; R2 is hydrogen, halogen, lower alkyl, cyano, C4-6-cycloalkyl, lower alkoxy, lower alkoxy substituted by halogen, or is a five- or six-membered heteroaryl, optionally substituted by lower alkyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.
    Type: Application
    Filed: July 21, 2016
    Publication date: November 10, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Katrin GROEBKE ZBINDEN, Emmanuel PINARD, Thomas RYCKMANS
  • Patent number: 9452980
    Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: September 27, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Katrin Groebke Zbinden, Roger Norcross, Philippe Pflieger